

PROVIDER BULLETIN

No. 15-27

Date: August 28, 2015

TO: Physicians and Mid-Level Practitioners Participating in the NE Medicaid Program

FROM: Calder Lynch, Director 
Division of Medicaid & Long-Term Care

BY: Leah Spencer, Program Specialist, R.N.
Division of Medicaid & Long-Term Care

RE: Hydroxyprogesterone Caproate Injection Update

Please share this information with administrative, clinical, and billing staff.

This Provider Bulletin replaces PB 11-33. The purpose of this Provider Bulletin is to clarify Nebraska Medicaid coverage of Hydroxyprogesterone Caproate for the prevention of pre-term birth in high risk women.

Hydroxyprogesterone Caproate is indicated to reduce the risk of pre-term birth in women and will only be covered when administered by a medical professional in a physician's office.

The following criteria for coverage must include:

- ◆ Singleton pregnancy and;
- ◆ History of spontaneous pre-term birth and;
- ◆ Injection initiated between 16th and ending at 37th week of gestation or birth, whichever comes first.

Claims for reimbursement of Hydroxyprogesterone must be submitted using the CMS-1500 Health Insurance Claim form with the correct HCPCS and a valid and rebateable NDC submitted with the claim. The compounded version of this product should use the correct HCPCS code and TH modifier.

Hydroxyprogesterone Caproate injection is a diagnosis-restricted drug. Supervision of pregnancy with history of pre-term labor is the only diagnosis code that will be allowed on claims for this drug. Claims with other diagnosis codes will be denied.

If you have questions about this information, please call Leah Spencer, Program Specialist at 402-471-9368, or via email at DHHS.MLTCPhysicalHealth@nebraska.gov.